Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Extracorporeal or ex vivo removal of antibodies or immune...
Reexamination Certificate
2006-03-21
2006-03-21
Andres, Janet L. (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Extracorporeal or ex vivo removal of antibodies or immune...
Reexamination Certificate
active
07014854
ABSTRACT:
A method for treating a condition related to the development of Alzheimer's disease (AD) is disclosed. The method involves the removal of circulating autoantibodies of a biochemical marker or markers, specifically human glial fibrillary acidic protein (GFAP) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), from the sera of a patient in an amount effective to reduce or eliminate phagocytosis of astrocytic cells. The invention further includes a process of immune system modulation effective for autoantibody removal.
REFERENCES:
patent: 4627915 (1986-12-01), Kurodo et al.
patent: 5004697 (1991-04-01), Pardridge
patent: 5098372 (1992-03-01), Jonsson
patent: 5627047 (1997-05-01), Brenner et al.
patent: 5723301 (1998-03-01), Burke et al.
patent: 5935927 (1999-08-01), Vitek et al.
patent: 6043224 (2000-03-01), Lee et al.
patent: 6187756 (2001-02-01), Lee et al.
patent: WO 93/10459 (1993-05-01), None
patent: WO 02/088706 (2002-11-01), None
Dermer, G. Bio/Technology, 12 :320, 1994.
Pardridge, W.M., Journal of Neurochem. 70: 1781-1792, 1998.
Sunaga, et al., “Glyceraldehyde-3-phosphate dehydrogenase is over-expressed during apoptotic death of neuronal cultures and is recognized by a monoclonal antibody against amyloid plaques from Alzheimer's brain”, Neuroscience Letters (1995) vol. 200, No. 2, pp. 133-136.
Borden, “Structure/Function in Neuroprotection and Apoptosis”, Annals of Neurology (1998) vol. 44, No. 3, pp. 565-571.
Terryberry, et al., “Autoantibodies in Neurodegenerative Diseases: Antigen-Specific Frequencies and Intrathecal Analysis”, Neurobiology of Aging (1998), vol. 19, No. 3, pp. 205-216.
Albrechtsen, et al., Enzyme-linked immunosorbent assay for the human glial fibrillary acidic protein using a mouse monoclonal antibody, (1985) vol. 11, No. 102, p 277.
Patent Abstracts of Japan, “Method and Device for Processing Blood By Plasma Exchange” vol. 1998, No. 8.
Hensley et al., A Model for β-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: Relevance to Alzheimer disease, Proc. Natl. Acad. Sci., (1994) 91, pp. 3270-3274.
Sunaga et al., “Glyceraldehyde-3-phosphate dehydrogenase is over-expressed during apoptotic death of neuronal cultures and is recognized by a monoclonal antibody against amyloid plaquest from alzheimer's brain”, Neuroscience Letters, (1995) 100, pp. 133-136.
Popovic et al., “Importance of immunological and inflammatroy processes in the pathogenesis and therapy of alzheimer's disease”, Int. J. Neurosci., (1998) 95, 3-4, pp. 203-236.
Joachim CL, et al., “Clinically diagnosed Alzheimer's disease: autopsy results in 150 cases”, (1988) Ann Neurol 24 (1): 50-6 (abstract only).
Mc Swigan JD, et al., “An analysis of glial fibrillary acidic protein in Alzheimer's disease”, (1983) Fed. Proc. 42 (7), abstract p. 1475.
Selkoe DJ, “Clearing the brain's amyloid cob webs”, (2001) Neuron 32: pp. 177-180.
Mecocci, et al., “Serum Autoantibodies against Glial Fibrillary Acidic Protein in Brain Aging and Senile Dementias”, Brain, Behavior, and Immunity (1992) 6: pp. 286-292.
Summary of I'ponna, et al.,Mental Disorders in Later Life(1956), pp. 289-331.
Ishida, et al., “Identification and characterization of an anti-glial fibrillary acidic protein antibody with a unique specificity in a demented patient with an autoimmune disorder”, J. Of Neurological Sciences (1997) 151: pp. 41-48.
Lopez et al., “Serum auto-antibodies in Alzheimer's disease”, Acta Neurol Scand (1991) 84: pp. 441-444.
Tanaka, et al., “Enzyme-linked immunosorbent assay for human autoantibody to glial fibrillary acidic protein: higher titer of the antibody is detected in serum of patients with Alzheimer's disease”, Acta Neurol. Scand (1989) 80: pp. 554-560.
Odabasi, et al., “Polyhydroxyethylmethacrylate-based magnetic DNA-affinity beads for anti-DNA antibody removal from systemic lupus erythematosus patient plasma”, Journal of Chromatography B (2001), 760(1): pp. 137-148.
Graninger et al., “Immunoadsorption Therapy (Therasorb) in Patients with Severe Lupus Erythematosus”, Acta Medica Austriaca-Heft 1 (2002) 29(1): pp. 26-29.
Suzuki, “The Role of Immunoadsorption Using Dextran-Sulfate Cellulose Columns in the Treatment of Systemic Lupus Erythematosus”, Therapeutic Apheresis (2000) 4(3): pp. 239-243.
Furesz Shirley
Jackowski George
Andres Janet L.
Chandra Gyan
McHale & Slavin P.A.
Syn X Pharma, Inc.
LandOfFree
Method for retarding or precluding Alzheimer's dementia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for retarding or precluding Alzheimer's dementia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for retarding or precluding Alzheimer's dementia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3608952